Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its earnings results on Monday. The biotechnology company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $1.41, FiscalAI reports.

Oramed Pharmaceuticals Stock Performance

ORMP stock traded down $0.10 during trading on Monday, reaching $4.20. 167,508 shares of the company traded hands, compared to its average volume of 231,258. Oramed Pharmaceuticals has a 12 month low of $1.98 and a 12 month high of $5.19. The company has a market capitalization of $174.72 million, a price-to-earnings ratio of 1.62 and a beta of 1.22. The business has a 50 day simple moving average of $4.12 and a 200 day simple moving average of $3.81.

Insider Activity at Oramed Pharmaceuticals

In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 73,360 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total value of $330,853.60. Following the completion of the sale, the chief financial officer directly owned 671,785 shares in the company, valued at $3,029,750.35. This trade represents a 9.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Joshua Hexter sold 137,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.46, for a total value of $611,020.00. Following the transaction, the chief operating officer owned 1,023,384 shares in the company, valued at approximately $4,564,292.64. This trade represents a 11.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.77% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in Oramed Pharmaceuticals in the fourth quarter valued at approximately $738,000. Bank of America Corp DE lifted its holdings in Oramed Pharmaceuticals by 4.4% in the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after acquiring an additional 6,261 shares during the period. Jane Street Group LLC lifted its holdings in Oramed Pharmaceuticals by 31.2% in the fourth quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 18,600 shares during the period. Squarepoint Ops LLC boosted its position in Oramed Pharmaceuticals by 95.1% in the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 28,406 shares in the last quarter. Finally, HRT Financial LP purchased a new stake in Oramed Pharmaceuticals in the 4th quarter worth approximately $131,000. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oramed Pharmaceuticals currently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.